Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Diseased human hepatocytes successfully reprogrammed into induced pluripotent stem cells

Diseased human hepatocytes successfully reprogrammed into induced pluripotent stem cells

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Alnylam to defend against Tekmira complaint

Alnylam to defend against Tekmira complaint

Global settlement agreement reached in Tuschl patents litigation

Global settlement agreement reached in Tuschl patents litigation

Study sheds light on novel functions of certain PCSK enzymes

Study sheds light on novel functions of certain PCSK enzymes

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

EPO upholds Alnylam's Tuschl II 1407044 patent

EPO upholds Alnylam's Tuschl II 1407044 patent

Aegerion third quarter net loss increases to $6.2 million

Aegerion third quarter net loss increases to $6.2 million

Impax initiates patent challenge in connection with SIMCOR

Impax initiates patent challenge in connection with SIMCOR

Chronic high fat cholesterol diet may lead to Alzheimer's disease

Chronic high fat cholesterol diet may lead to Alzheimer's disease

Impax initiates challenge of patents relating to WELCHOL

Impax initiates challenge of patents relating to WELCHOL

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.